Cargando…

Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study

Relapse is the main cause of treatment failure for leukaemia patients with unfavourable gene mutations who receive allogeneic haematopoietic stem cell transplantation (allo‐HSCT). There is no consensus on the indication of donor lymphocyte infusion (DLI) for prophylaxis of relapse after allo‐HSCT. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Rui, Wang, Lili, Chen, Peng, Gao, Xiaoning, Wang, Shuhong, Li, Fei, Dou, Liping, Gao, Chunji, Li, Yan, Liu, Daihong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124122/ https://www.ncbi.nlm.nih.gov/pubmed/33932107 http://dx.doi.org/10.1002/cam4.3763

Ejemplares similares

A phase II study of chidamide, cytarabine, aclarubicin, granulocyte colony-stimulating factor, and donor lymphocyte infusion for relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation
por: Wei, Yan, et al.
Publicado: (2023)

Reduced risk of chronic GVHD by low-dose rATG in adult matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies
por: Dou, Liping, et al.
Publicado: (2019)

Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies
por: Dou, Liping, et al.
Publicado: (2021)

Effects of decitabine on allogeneic immune reactions of donor lymphocyte infusion via activation of dendritic cells
por: Kwon, Yong-Rim, et al.
Publicado: (2020)

Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial
por: Gao, Lei, et al.
Publicado: (2020)

Improved donor chimerism in relapse myelofibrosis post allogenic stem cell transplant with azacitidine and oral decitabine—First case report
por: Cheung, Verna, et al.
Publicado: (2022)

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
por: Platzbecker, U, et al.
Publicado: (2012)

Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant
por: Rahmat, Leena T., et al.
Publicado: (2018)

2737. Real World Evaluation of Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant (aHSCT) Patients, Is Routine Antifungal Prophylaxis Needed?
por: Perreault, Sarah, et al.
Publicado: (2023)

Allogeneic HSCT in Adolescents and Young Adults With Primary Immunodeficiencies
por: Morris, Emma C., et al.
Publicado: (2019)

Editorial: Novel Immunological Biomarkers for Allogeneic HSCT Outcome
por: Greco, Raffaella, et al.
Publicado: (2021)

High-dose aciclovir in CMV infection prophylaxis after allogeneic HSCT: a single-center long-term experience
por: Kabut, Tomáš, et al.
Publicado: (2023)

Decitabine-based chemotherapy followed by haploidentical lymphocyte infusion improves the effectiveness in elderly patients with acute myeloid leukemia
por: Jing, Yu, et al.
Publicado: (2016)

Mesenchymal stem cells provide prophylaxis against acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: A meta-analysis of animal models
por: Wang, Li, et al.
Publicado: (2016)

The effect of decitabine-combined minimally myelosuppressive regimen bridged allo-HSCT on the outcomes of pediatric MDS from 10 years’ experience of a single center
por: Gao, Junyan, et al.
Publicado: (2022)

GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma
por: Muranushi, Hiroyuki, et al.
Publicado: (2020)

Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning
por: Iwasaki, Makoto, et al.
Publicado: (2022)

S247: ADDING RUXOLITINIB AND DECITABINE TO BU/CY CONDITIONING REGIMENS TO PROPHYLAXIS POST-TRANSPLANT RELAPSE IN HIGH-RISK AML IS SAFE AND EFFECTIVE: A PROSPECTIVE, PHASE II STUDY
por: Wei, Yujun, et al.
Publicado: (2023)

Use of micafungin as antifungal prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Spain (GETH-MIC)
por: López-Sánchez, Cristina, et al.
Publicado: (2020)

Combination of Donor Lymphocyte Infusion and Blinatumomab for B-Cell Lymphoblastic Lymphoma Relapse after Allogeneic Stem-Cell Transplantation
por: Mori, Jinichi, et al.
Publicado: (2023)

Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors
por: Liberatore, Carmine, et al.
Publicado: (2022)

The Role of Donor Leukocyte Infusions in the Treatment of Relapsed Acute Leukemia after Allogeneic Stem Cell Transplantation: A Retrospective Analysis
por: Vaezi, Mohammad, et al.
Publicado: (2018)

Impact of donor vaccination on recipient response to early SARS-CoV-2 mRNA vaccination after allogeneic HSCT
por: Leclerc, Mathieu, et al.
Publicado: (2022)

Biological and Genetic Aspects of Donor-Recipient Matching in HSCT
por: Lange, Andrzej, et al.
Publicado: (2012)

P1298: THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED CONDITIONING REGIMEN FOR ALLOGENEIC-HSCT IN REFRACTORY/RELAPSED OR PERSISTENT MRD POSITIVITY AML PATIENTS
por: Jiang, Erlie, et al.
Publicado: (2023)

CT-365: The Evaluation of Haematological and Biochemistry Parameters in COVID-19 Patients as a Predictive Factor for Unfavourable Evolution
por: Popov, Viola, et al.
Publicado: (2020)

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
por: Goswami, Meghali, et al.
Publicado: (2022)

Case report: HLA-haploidentical HSCT rescued with donor lymphocytes infusions in a patient with X-linked chronic granulomatous disease
por: Scheiermann, Julia, et al.
Publicado: (2023)

Early CD8(+)-recovery independently predicts low probability of disease relapse but also associates with severe GVHD after allogeneic HSCT
por: Ranti, Juha, et al.
Publicado: (2018)

Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome
por: Kong, Jun, et al.
Publicado: (2022)

Allogeneic HSCT for Symptomatic Female X-linked Chronic Granulomatous Disease Carriers
por: Tsilifis, Christo, et al.
Publicado: (2023)

Multiple breath washout and oscillometry after allogenic HSCT: a scoping review
por: Sonneveld, Nicole, et al.
Publicado: (2023)

Survival Analysis of Transplant-Associated Thrombotic Microangiopathy Under Different Diagnostic Criteria and Efficacy of Plasma Exchange
por: Xu, Yifan, et al.
Publicado: (2023)

Harnessing allogeneic NK cells: improving outcomes with tailored donor lymphocyte infusion
por: McCurdy, Shannon R.
Publicado: (2022)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Treatment of relapsed acute leukemia by Ara C plus donor lymphocyte infusion using CD34＋ cells reserved at the time of allogeneic transplantation
por: YJ, Lee, et al.
Publicado: (2020)

Granulocytic sarcoma as isolated extramedullary relapse after donor lymphocyte infusion in a patient with CML who relapsed after allogeneic bone marrow transplantation: a case report.
por: Lee, J. J., et al.
Publicado: (1998)

Unfavourable results in pollicisation
por: Thatte, Mukund R., et al.
Publicado: (2013)

Unfavourable results in hypospadias
por: Agrawal, Karoon, et al.
Publicado: (2013)

Ruxolitinib treatment for acute gastrointestinal graft-versus-host disease caused by donor-derived CD19-Chimeric antigen receptor T-Cell infusion in a patient with B-ALL relapsed after Allo-HSCT
por: Yang, Yingying, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nks8q6emm3q5qnfcqsous3bvpo